Effect of switching from high dose fluticasone propionate (FP) to FP/salmeterol (FSC) on airway inflammation in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 44s Year: 2004
Variability in asthma and treatment efficacy as determined by weekly response rates with fluticasone propionate/salmeterol 100/50mcg (FSC) compared with montelukast 10mg (MON) Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo Source: Eur Respir J 2001; 18: Suppl. 33, 123s Year: 2001
"Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice Source: Eur Respir J 2006; 28: Suppl. 50, 713s Year: 2006
Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Airway hyperresponsiveness and treatment effectiveness during a one year study of the combination of salmeterol and fluticasone propionate (FP) compared with FP and salmeterol alone in mild to moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
In vivo dose response relation of inhaled fluticasone propionate (FP), adults with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Late Breaking Abstract - Dose responses for topical efficacy and systemic activity, dose equivalence and relative therapeutic index for fluticasone furoate (FF), fluticasone propionate (FP) and budesonide (BUD) in asthmatic subjects. Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Effect of addition of salmeterol vs doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
The safety of double dose salmeterol/fluticasone proprionate (SFC) in adult asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), demonstrates efficacy in asthma patients symptomatic on moderate doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
Comparison of salmeterol/fluticasone propionate (sal/fp) combination versus monotherapy with fluticasone propionate (fp) in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004